All In Biotech

Drug Trial Radar · NCT06886464

Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin

The Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin (PONTiAK) Trial: A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 698 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

698

Planned (sponsor's estimate)

Start

Jul 16, 2025

Primary completion

Dec 31, 2027

Study completion Dec 2029

Sponsor

Lead sponsor
Matthew JamesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alberta Health services; University of Alberta
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to repurpose cilastatin for preventing acute kidney injury (AKI) in hospitalized patients receiving nephrotoxic medications. The trial will evaluate the efficacy of the re-purposed drug. The main questions it aims to answer are: \- whether cilastatin will prevent nephrotoxic AKI in hospitalized patients. Researchers will compare the drug cilastatin to a placebo (a look-alike substance that contains no drug) to see if drug cilastatin works to prevent AKI in hospitalized patients receiving nephrotoxic medications. Participants will: * Receive drug Cilastatin or a placebo intravenously every 6 hours for up to 24 hours after last exposure to nephrotoxic medication * Have blood test for kidney function every day they are on treatment. * Have a follow-up blood test at 90 days after randomization * Have a telephone survey at 90 days after randomization

Conditions

  • Acute Kidney Injury

Interventions

  • Cilastatin SodiumDrug

    Intravenous cilastatin reconstituted in normal saline solution

  • Placebo-SalineDrug

    Identical looking normal saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants developing AKITime frame: 7 days after administration of a nephrotoxic medication

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta

    Edmonton, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.